Certain GLP-1 drugs, including semaglutide and tirzepatide, are FDA-approved for specific uses such as treating type 2 diabetes and, in certain cases, chronic weight management
That evidence may matter significantly for patients with: Prior heart attack Stroke history Significant cardiovascular risk factors Patients Who Prefer Weekly Rather Than Daily Dosing Some people are actually more consistent with once-weekly routines than with daily medications
Moderate adverse effects include dizziness, mild increased heart rate, infections, headaches, and indigestion
The REWIND trial investigated the cardiovascular benefits of dulaglutide, a GLP-1 receptor agonist, in a population of 9,901 patients with T2DM aged 50+ and either established CVD or risk factors
How to Enjoy the World Games in Miami the Wellness Way By Dr